FDA

cemetery

Is This the End of Sunesis?

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) probably wishes that this Friday never happened. The company was already a very speculative cancer drug biotech outfit, and now its status is moving down ...
Read Full Story »
Sad lonely pensive old senior woman

Is This the End for XOMA?

XOMA Corp. (NASDAQ: XOMA) stumbled in trading Wednesday morning, perhaps fell off a cliff might be more accurate. In only the first hour of trading alone, over 22 million shares ...
Read Full Story »
health care

What FDA Breakthrough Therapy Designation Means for Dyax

Dyax Corp. (NASDAQ: DYAX) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted a key breakthrough therapy designation for the investigation of DX-2930 for hereditary angioedema ...
Read Full Story »
fda_logo

5 Big Upcoming FDA Decisions Expected in July

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
biotech

Sarepta Takes Its Foot off the Gas

Considering that a Greek exit might be on the way, the broad markets have sold off a fair amount, and across the markets companies are losing out. Sarepta Therapeutics Inc. ...
Read Full Story »
145922793

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. This covers a new class of drugs in the PCSK9 classification, and FDA panels are ...
Read Full Story »
health care

6 Key Cancer Winners From ASCO Presentations

The American Society of Clinical Oncology, or ASCO, is currently having its annual meeting, in which companies and cancer drug developers share results from their most recent drug trials. The ...
Read Full Story »
fda_logo

How Sarepta Short Interest Is Adding to Its Gains

Usually, when biotech companies meet with the U.S. Food and Drug Administration (FDA), their stock goes one of two ways. In the case of Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares ...
Read Full Story »
DNA

Why This Study May Have Saved Pain Therapeutics

Both biotech and pharmaceutical companies have a mission to make life better for everyone through the innovation and production of drugs that can save lives. Pain Therapeutics Inc. (NASDAQ: PTIE) ...
Read Full Story »
Money background. Close-up.

What Is Really Driving Array Higher

Array BioPharma Inc. (NASDAQ: ARRY) released is fiscal third-quarter earnings before the markets opened Monday. The company reported a net loss of $0.11 per share on $6.6 million in revenue for the ...
Read Full Story »
health care

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

The trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics ...
Read Full Story »
145922793

A Real Heartbreak for Celladon

On its website, Celladon Corp. (NASDAQ: CLDN) writes “Hope to Heart Patients.” Not to sound morbid, but the company appears to have lost at least some hope – in terms of dollars ...
Read Full Story »
upgrade

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

GW Pharmaceuticals PLC (NASDAQ: GWPH) was recently listed as the top medical marijuana stock for National Weed Day, but other things are going on here besides weird holidays. GW recently ...
Read Full Story »
chicks

How Much Do Companies Really Have to Worry About Bird Flu?

The world has never been able to get past the fears of viruses, outbreaks and contagion. Now bird flu is making its way back into the news, and the fears of ...
Read Full Story »
research

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »